Advertisement

Journal of Radiation Oncology

, Volume 8, Issue 2, pp 171–175 | Cite as

Changes in prostate-specific antigen midway through salvage radiotherapy may be associated with long-term outcomes

  • Jason M. Homza
  • John T. Nawrocki
  • Harmar D. Brereton
  • Christopher A. PetersEmail author
Original Research
  • 8 Downloads

Abstract

Objective

To examine the relationship between changes in prostate-specific antigen (PSA) by midpoint of salvage radiotherapy (SRT) for biochemically recurrent prostate cancer and long-term clinical outcomes.

Methods

We conducted a retrospective study of men treated with SRT for biochemically recurrent prostate cancer at a single practice from 2004 to 2016. Patients were grouped based on PSA response at treatment midpoint: group 0, no change; group 1, decrease; group 2, increase. The primary endpoint was clinical failure measured from time of SRT completion and defined as serum PSA ≥ 0.2 ng/mL above post-radiotherapy nadir, initiation of androgen deprivation therapy, development of bone metastasis, or death from prostate cancer. The Kaplan-Meier method was used to estimate freedom from clinical failure for each group, and differences between groups were examined using pairwise multiple comparison.

Results

Median follow-up was 51.6 months (range, 3.3–138.0). Of 76 eligible men, 13.1% experienced no change in PSA at midpoint of SRT (group 0), 68.4% experienced a decrease (group 1), and 18.4% experienced an increase (group 2). Four-year freedom from clinical failure rates were as follows: group 0, 60.0%; group 1, 58.3%; and group 2, 41.7%. Median time to clinical failure was 71.7 months (95% confidence interval, 46.9–96.5) for group 1; 26.8 months (95% confidence interval, 0.0–55.9) for group 2; and was not reached for group 0. There was a significant difference in four-year freedom from clinical failure between groups 1 and 2 (p = 0.036).

Conclusions

PSA changes by the midpoint of SRT predict long-term prostate cancer control with increases in PSA associated with decreased freedom from disease progression.

Keywords

Prostate cancer Salvage radiation therapy Biochemical recurrence Prostate-specific antigen PSA 

Notes

Acknowledgments

We thank Madhava Baikadi, M.D.; Thomas Churilla, M.D.; Meghan Haggerty, M.D.; Leah Nawrocki, RN, MSN; Mushfiq Tarafder, Ph.D., MPH, MBBS; Jim Walker; and the nurses and staff of Northeast Radiation Oncology Center for providing support for the study.

Compliance with ethical standards

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2):307–314.  https://doi.org/10.1002/cncr.23161 CrossRefGoogle Scholar
  2. 2.
    Sheets NC, Hendrix LH, Allen IM, Chen RC (2013) Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results Medicare analysis. Cancer 119(18):3295–3301.  https://doi.org/10.1002/cncr.28222 CrossRefGoogle Scholar
  3. 3.
    Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190(2):441–449.  https://doi.org/10.1016/j.juro.2013.05.032 CrossRefGoogle Scholar
  4. 4.
    Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291(11):1325–1332CrossRefGoogle Scholar
  5. 5.
    Zumsteg ZS, Daskivich TJ, Sandler HM (2016) Salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy. J Clin Oncol 34:3829–3833.  https://doi.org/10.1200/jco.2016.69.2509 CrossRefGoogle Scholar
  6. 6.
    Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041.  https://doi.org/10.1200/jco.2006.08.9607 CrossRefGoogle Scholar
  7. 7.
    Patel AR, Stephenson AJ (2011) Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nat Rev Urol 8(7):385–392.  https://doi.org/10.1038/nrurol.2011.80 CrossRefGoogle Scholar
  8. 8.
    Neuhof D, Hentschel T, Bischof M, Sroka-Perez G, Hohenfellner M, Debus J (2007) Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 67(5):1411–1417.  https://doi.org/10.1016/j.ijrobp.2006.11.024 CrossRefGoogle Scholar
  9. 9.
    Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W (2009) Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Int J Radiat Oncol Biol Phys 73(4):1009–1016.  https://doi.org/10.1016/j.ijrobp.2008.06.1922 CrossRefGoogle Scholar
  10. 10.
    Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417–428.  https://doi.org/10.1056/NEJMoa1607529 CrossRefGoogle Scholar
  11. 11.
    Pollack A ea. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPort trial. vol Abstract LBA-5. ASTRO 2018Google Scholar
  12. 12.
    Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF 3rd, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL (2017) Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol 35(9):542.e525–542.e532.  https://doi.org/10.1016/j.urolonc.2017.04.018 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Jason M. Homza
    • 1
  • John T. Nawrocki
    • 1
  • Harmar D. Brereton
    • 1
    • 2
  • Christopher A. Peters
    • 1
    • 2
    Email author
  1. 1.Geisinger Commonwealth School of MedicineScrantonUSA
  2. 2.Northeast Radiation Oncology CenterDunmoreUSA

Personalised recommendations